Company Medivir AB (publ) OTC Markets

Equities

MVRBF

SE0020181014

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Bio Therapeutic Drugs

Inactive Instrument

Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.

Number of employees: 10

SEK in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	4	100.0 %	8	100.0 %	+73.16%

SEK in Million	2022	Weight	2023	Weight	Delta
United States 46.9 %	-	-	4	46.9 %	-
Europe, Other 43.3 %	4	80.8 %	3	43.3 %	-7.16%
Rest of the World 4.8 %	0	9.9 %	0	4.8 %	-16.21%
Sweden 2.5 %	0	5.0 %	0	2.5 %	-13.12%
Nordic Region, Other 2.4 %	0	4.2 %	0	2.4 %	-0.53%

Managers	Title	Age	Since
Jens Lindberg CEO	Chief Executive Officer	53	22-01-23
Magnus Christensen DFI	Director of Finance/CFO	50	19-08-11
Uli Alf Hacksell CHM	Chairman	74	18-05-02
Pia Baumann CTO	Chief Tech/Sci/R&D Officer	58	23-02-19
Malene Jensen CTO	Chief Tech/Sci/R&D Officer	54	21-09-30
Fredrik Öberg CTO	Chief Tech/Sci/R&D Officer	59	10-12-31
Yilmaz Mahshid BRD	Director/Board Member	45	20-05-25

Members of the board	Title	Age	Since
Uli Alf Hacksell CHM	Chairman	74	18-05-02
Stig Lennart Hansson BRD	Director/Board Member	68	18-05-02
Yilmaz Mahshid BRD	Director/Board Member	45	20-05-25
Bengt Westermark BRD	Director/Board Member	79	17-05-02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	864,750	0	864,750 ( 100.00 %)	68.69 %
Stock B	1	104,506,048	72,375,356 ( 69.25 %)	11,413 ( 0.0109 %)

Name	Equities	%	Valuation
Nordea Investment Management AB 9.226 %	10,338,122	9.226 %	3 M $
Livförsäkringsbolaget Skandia, ömsesidigt 0.8466 %	948,688	0.8466 %	243 765 $
Uli Alf Hacksell 0.4902 %	549,265	0.4902 %	141 134 $
FCG Fonder AB 0.3350 %	375,361	0.3350 %	96 449 $
Alfred Berg Kapitalförvaltning AB 0.1712 %	191,825	0.1712 %	49 289 $
Storebrand Asset Management AS 0.0968 %	108,418	0.0968 %	27 858 $
Swedbank Robur Fonder AB 0.0828 %	92,732	0.0828 %	23 827 $
Delta Lloyd Asset Management NV 0.0724 %	81,137	0.0724 %	20 848 $
Holberg Fondsforvaltning AS 0.0517 %	57,952	0.0517 %	14 891 $
Gustavia Fonder AB 0.0417 %	46,750	0.0417 %	12 012 $

Medivir AB

Lunastigen 5 2nd Floor

141 22, Huddinge

+46 8 54 68 31 00

http://www.medivir.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-15.84%	21.4B
GENMAB A/S	-10.00%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-14.65%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.83B
SAREPTA THERAPEUTICS, INC.	+31.35%	11.97B

Bio Therapeutic Drugs